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Introduction: We aimed to investigate the expression and therapeutic modulation of the receptor activator of the
NF-κB ligand (RANKL) system in early-untreated rheumatoid arthritis (RA).
Methods: In this study, 15 patients with newly diagnosed RA (median symptom duration 7 months) were started
on methotrexate (MTX) 20 mg weekly. Synovial biopsies were obtained by needle arthroscopy at baseline and
8 weeks after initiation of therapy. X-rays of the hands and feet were obtained at baseline and 1 year after diagnosis.
Immunohistochemistry was performed to detect RANKL, receptor activator of nuclear factor-κB (RANK) and
osteoprotegerin (OPG) in the synovial biopsies. The in vitro effect of MTX was tested on RA-derived primary fibroblasts
and the osteoblasts-like osteosarcoma cell line (rtPCR, Western blot and ELISA) and in osteoclasts (tartrate-resistant acid
phosphatase staining and dentine pit formation assay).
Results: MTX decreased synovial cellularity as well as RANK expression and the RANKL/OPG ratio. We confirmed this
effect by a decrease of the mRNA and protein RANKL/OPG ratio in synovial-derived fibroblasts and osteoblasts-like
tumoral cells exposed in vitro to methotrexate. Supernatants from MTX treated osteoblasts-like tumoral cells prevented
pre-osteoclast formation in the absence of exogenous RANKL. Furthermore, MTX blocked osteoclastogenesis from
peripheral blood mononuclear cells despite the presence of macrophage colony stimulating factor and RANKL, which
indicates that MTX directly inhibits osteoclastogenesis.
Conclusions: The synovial membrane of early-untreated RA is characterized by a high RANKL/OPG ratio that can be
reversed by methotrexate.Introduction
Rheumatoid arthritis (RA) is a chronic inflammatory dis-
ease characterized by synovial inflammation and bone
destruction in the absence of early and aggressive thera-
peutic intervention [1]. Bone destruction is controlled by
the complex interplay between three molecules essential
for bone biology: a receptor (receptor activator of NF-κB
(RANK)), a ligand (receptor activator of the NF-κB ligand
(RANKL)) and a soluble decoy receptor (osteoprotegerin
(OPG)) [2]. In RA it has been postulated that bone de-
struction occurs as a direct consequence of inflammation.* Correspondence: shankar.revu@gmail.com; anca.catrina@ki.se
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reproduction in any medium, provided the orThis has been challenged recently by the observation that
bone destruction can occur in RA despite clinical remis-
sion [3,4], while specific anti-rheumatic drugs might pro-
tect against destruction even in the absence of clinical
remission [5,6]. Taken together these findings suggest that
inflammation and bone destruction are at least partially
uncoupled in RA.
RANKL, RANK and OPG are all expressed in the in-
flamed synovium of RA and specifically modulated by dis-
tinct anti-rheumatic drugs. We have previously shown
that anti-tumor necrosis factor (TNF) agents and gluco-
corticoids directly modulate the RANKL system in human
RA [7,8]. More recent animal studies have demonstrated a
bone-protective effect of methotrexate (MTX) [9,10], aba-
tacept [11] and tocilizumab [12]. To date no study tod. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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its modulation by MTX is currently available. We there-
fore aimed to characterize RANKL, RANK and OPG ex-
pression in the synovial membrane of early-untreated RA
in relation to local inflammation and disease activity and
to investigate how expression of these molecules might
change following MTX treatment.
Methods
Patients
Fifteen patients (10 women and five men, median age
56 years, range 33 to 78 years) with new diagnosed RA
(patient-reported symptom duration <1 year, median
symptom duration 7 months, range 2 to 12 months) ac-
cording to 1987 American College of Rheumatology cri-
teria [13], previously disease-modifying anti-rheumatic
drug naïve, were started on MTX 10 mg weekly and
reached a stable dose of 20 mg after 2 weeks of increas-
ing the dose by 5 mg each week. Synovial biopsy samples
were obtained by arthroscopy from all patients before
and after a median of 8 weeks of treatment. Clinical
evaluation and evaluation of the therapeutic response
according to European League Against Rheumatism
(EULAR) response criteria (a median of 3 months after
MTX initiation) were performed by a rheumatologist.
X-ray scans of hands and feet were obtained at baseline
and 1 year after diagnosis. Nonsteroidal anti-inflammatory
drugs, per oral prednisolone to a maximum dose of
10 mg daily and intraarticular glucocorticoid injections
in joints other than the one subjected to biopsy were
permitted according to clinical indication. Additional
file 1 summarizes the demographic characteristics of
the patients. All procedures where approved by the
Northern Stockholm Ethical Review Board and in-
formed consent was obtained from all the participants
in the study.
Immunohistochemistry evaluation
Presence of RANKL, RANK and OPG was detected
using the following monoclonal antibodies: anti-human
RANKL antibody at a final concentration of 5 μg/ml
(12A668; Abcam, Cambridge, UK), anti-human RANK
antibody at a final concentration of 5 μg/ml (9A725;
Abcam) and anti-human OPG antibody (MAB805; R&D
Systems, Minneapolis, MN, USA) at a concentration of
2.5 μg/ml, using a previously published protocol [7]. We fur-
ther characterized the synovial cell phenotype using several
monoclonal antibodies: anti-human CD3 antibody (347340;
BD Biosciences San Jose, CA, USA), anti-human CD68 anti-
body (M0814; DakoCytomation, Glostrup, Denmark), anti-
human CD31 antibody (clone EN4, MON6002; Novakemi
Ab, Uden, the Netherlands), anti-human CD138 antibody
(B-A38; Diaclone Res, Besancon, France) and anti-human
CD19 antibody (HD37; DakoCytomation). The isotypeof all primary antibodies was IgG1 and a concentration-
matched mouse IgG1 was used as the negative control
(DakoCytomation).
Synovial biopsy sections were evaluated semiquantita-
tively, using a four-point scale (0 = no staining, 1 = low
amounts of staining, 2 = moderate amounts of staining,
3 = high amounts of staining) by two independent ob-
servers (SR and AIC) who were unaware of the patient’s
identity and biopsy sequence, as described previously [8].
Final scores represent the means of the two independent
observations. For quantification, synovial expression of
three of the stained markers (RANKL, RANK and OPG)
was evaluated using computer-assisted image analysis
(250× magnifications) as described previously [7].
Cell culture and western blot analysis
The human osteoblast-like sarcoma cell line (SaOS2)
was purchased from DSMZ (Braunschweig, Germany),
and cultured in McCoy’s 5A medium (Invitrogen, Carlsbad,
CA, USA). RA synovial-derived fibroblasts from two differ-
ent donors were purchased from Dominion Pharmakine
(Deiro, Bizkaia, Spain) and cultured in Dulbecco’s modified
Eagle’s medium. All media were supplemented with 10%
heat-inactivated fetal bovine serum. All reagents were pur-
chased from Gibco (Carlsbad, CA, USA).
Cells were seeded at a density of 107 cells/ml on 10 cm
dishes at 37°C in a humidified atmosphere with 5% carbon
dioxide and incubated with or without MTX at a final con-
centration of 1, 10 or 100 μM. After 24 hours cells were
washed with cold phosphate-buffered saline (PBS) and whole
cell lysates were prepared with RIPA buffer containing
50 mM Tris HCl, pH 7.5, 150 mM NaCl, Igepal CA-630 (all
reagents from Sigma, Stockholm, Sweden), and complete
protease inhibitor cocktail tablet (Roche, Basel, Switzerland).
Lysed cells were centrifuged to remove debris at 14,000 rpm
for 15 minutes at 4°C and supernatants were collected. A
total of 40 μg cellular protein (measured using the Bradford
assay and bovine serum albumin as standards) was loaded
into sodium dodecyl sulphate polyacrylamide gel electro-
phoresis under nonreducing conditions. Following electro-
phoresis, proteins were transferred on to a Polyvinylidene
difluoride (PVDF) membrane and blocked with 5% nonfat
milk in 0.1% PBS/Tween 20 for 1 hour at room temperature.
The membrane was incubated with either anti-human
RANKL or anti-human OPG mouse monoclonal antibodies
at a final concentration of 2 μg/ml in 0.1% PBS/Tween 20 at
4°C overnight. After washing, the membrane was incubated
with secondary peroxidase-linked anti-mouse IgG (NXA931;
Amersham Biosciences, Buckinghamshire, UK) diluted in
0.1% PBS/Tween 20 diluted 1:3,000 for 1 hour at room
temperature. After washing the membrane, protein bands
were visualized on X-ray film using enhanced chemilu-
minescence (RPN2209; Amersham Biosciences). For ana-
lyzing the protein expression, band intensity was measured
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β-actin. All experiments were run in triplicate and were re-
peated at least four times.
Enzyme-linked immunosorbent assay
All culture supernatants were centrifuged and stored
at −20°C for a short time with no thawing/freezing cycles
until quantified. Samples were assayed using commer-
cially available kits for RANKL (BI-202452) and OPG
(BI-20402) using a sandwich enzyme immunoassay ac-
cording to the manufacturer’s instructions (Biomedica,
Vienna, Austria). All samples were analyzed as duplicates
from at least three independent experiments. The concen-
tration of the samples was calculated from the standard
curve using a 4PL algorithm and expressed as picomoles
per liter. All experiments were run in triplicate and were
repeated at least four times.
Quantitative reverse transcriptase-polymerase chain
reaction
Total RNA was isolated from Saos2 cells using the
RNeasy mini purification Kit (Qiagen, Hilden, Germany)
and cDNA was obtained using the Super Script cDNA
synthesis kit (Invitrogen). RANKL and β-actin mRNA
expression was detected by Taqman Gene Expression
Assay Hs00243522 and Hs99999903 respectively (Applied
Biosystems, Carlsbard, CA, USA). The mRNA expression
of other genes was detected using the Power SYBR Green
PCR Master Mix (Applied Biosystems, Warrington, UK).
Primer sequences are provided in Additional file 2.
The amplification conditions used for all genes were
10 minutes at 95°C followed by two-step cycling polymer-
ase chain reaction for 40 cycles at 95°C for 15 seconds and
at 60°C for 1 minute. All experiments were run in tripli-
cate and were repeated at least four times.
Osteoclastogenesis and bone destruction assay
CD14+ cells were isolated from healthy donor peripheral
blood mononuclear cells (PBMCs) using magnetically
labeled CD14 microbeads (130-050-201; Miltenyi Biotec,
Bergisch Gladbach, Germany). CD14+ cells were collected
and seeded at a density of 0.5 × 105 cells/ml in Dulbecco’s
modified Eagle’s medium containing 10% heat-inactivated
fetal bovine serum either in chamber slides (177445; Nalge
Nunc, Rochester, NY, USA) or on synthetic bone discs
(BD BioCoat Osteologic Bone cell culture system,
354610; Discovery Labware, San Jose, CA, USA). After
3 days the supernatant was removed and cells were incu-
bated with conditioned supernatants from osteoblast-like
cells previously incubated with or without MTX. Cells
were further incubated for 14 days and the supernatant
exchanged with new batches of the conditioned medium
every 3 days in the presence of macrophage colony-
stimulating factor (M-CSF). After 12 days, cells seededon chamber slides were washed once with PBS and
stained using a tartrate-resistant acid phosphatase (TRAP)
staining kit according to the manufacturer’s instructions
(387-A; Sigma Aldrich, Stockholm, Sweden). Pre-osteoclast
formation was evaluated as the percentage of TRAP-
positive mononuclear and binuclear stained cells out of the
total number of cells.
Alternatively, CD14+ PBMCs were cultured in the
presence of 25 ng/ml human M-CSF (216-MC; R&D)
and 50 ng/ml human RANKL (390-TN-010; R&D) with
or without MTX to a final concentration of 0, 1, 10
or 100 μM. During incubation, fresh medium with
differentiation factors and MTX were changed every
3 days for chamber slide cultures and every 7 days
for bone disc cultures. After 14 days, cells seeded on
chamber slides were washed once with PBS and
stained using a TRAP staining kit according to the
manufacturer’s instructions (387-A; Sigma Aldrich).
Osteoclast formation was evaluated as the percentage
of TRAP-positive stained multinuclear cells (≥3 nu-
clei) and pre-osteoclast formation was evaluated as
the percentage of TRAP-positive mononuclear and
binuclear stained cells out of the total number of
cells. After 21 days, supernatants from the bone disc
cultures were removed and the disks washed twice in
distilled water, followed by extensive washing with 6%
chlorine water until the cells dislodge from the discs
and a final washing step with distilled water. Resorp-
tion areas were examined under normal light micro-
scope and pictures were analyzed using Image J and
Photoshop.
Survival assay
Osteoclast precursors, osteoblast-like tumoral cells, syn-
ovial fibroblasts and PBMC were cultured with or with-
out MTX at a final concentration of 100 μM. After
7 days, adherent and nonadherent cells were collected
by gentle scraping and analyzed by flow cytometry ana-
lysis using the TACS Annexin V-FITC apoptosis detec-
tion kit (R&D Systems). Apoptotic cells were defined as
Annexin-V-positive cells and expressed as a percentage
of the total number of cells.
Statistical analysis
Statistical analysis was performed using the Wilcoxon
test for comparison of paired samples, the Mann–
Whitney test for comparison of independent samples
and the Spearman test for correlations. No mathemat-
ical correction for multiple comparisons was applied.
Differences between proportions were analyzed by
Fisher’s exact test. In vitro experiments results were
analyzed using one-way analysis of variance as appro-
priate and the Dunnett post hoc test. P <0.05 was consid-
ered statistically significant.
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Methotrexate prevents radiographic progression in some
but not all RA patients, independent of the clinical
therapeutic response
Treatment with MTX resulted in clinical improvement
with a significant decrease of the 28-joint Disease Activity
Score from a mean ± standard error of the mean of 5.6 ±
0.2 before treatment to 3.5 ± 0.3 at 2 months after
treatment initiation (P <0.05). A majority of the pa-
tients (13/15, 86%) achieved EULAR criteria for response
(either good responders 6/15, 40%; or moderate re-
sponders 7/15, 47%), while two patients (2/15, 13%) were
nonresponders. Erosions of hands and/or feet were
present in two out of 15 patients at baseline (13%) and in
six out of 14 patients at 1-year follow-up (40%, oneFigure 1 Methotrexate decreases lymphocyte and macrophage infiltr
arthritis. Brown immunohistochemistry (diaminobenzidine) staining of cell
Synovial CD3 expression in early-untreated RA synovium (A) decreased signifi
CD68 expression in early, untreated RA synovium (D) decreased significantly f
untreated RA (G) is not changed following 8 weeks of MTX treatment (H). Re
(C), CD68 (F) and CD31 (I) expression before and 8 weeks after MTX treatmenmissing data). Development of new erosions was identified
in five out of 14 patients (30%, one missing data) at 1-year
follow-up. Among these five patients, one (20%) was a
EULAR nonresponder to therapy and four (80%) were re-
sponders. Among patients with no progression at follow-
up, one out of 10 (10%) were EULAR nonresponders and
nine (90%) were EULAR responders.
Methotrexate treatment reduces synovial inflammation
Immunophenotyping of the synovial cells revealed a sig-
nificant decrease of the lymphocyte CD3-positive popu-
lation (from a median of 1.5 (range 1 to 3) to a median
of 1 (range 1 to 3), P <0.05; Figure 1A,B,C) and the
CD68 population (from a median of 2 (range 1.5 to 3) to
a median of 1.5 (range 1 to 3), P <0.05; Figure 1D,E,F),ation in the rheumatoid synovium of early-untreated rheumatoid
surface markers in synovial biopsies of early rheumatoid arthritis (RA).
cantly following 8 weeks of methotrexate (MTX) treatment (B). Synovial
ollowing 8 weeks of MTX treatment (E). Synovial CD31 expression in early,
sults from the semi-quantitative double-blind analysis of synovial CD3
t. *p<0.05.
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synovial blood vessel size (P >0.05; Figure 1G,H,I). No
changes in expression of CD19, CD138 or CD55 were
observed (data not shown). No correlation between
changes in synovial cell surface markers and changes in
disease activity score was observed.
Methotrexate significantly downregulates synovial
expression of RANKL and RANK and decreases the
RANKL/OPG ratio
Changes in cellularity were accompanied by changes in
local expression of RANKL with a significant decrease
from a median score of 2 (range 1.5 to 3) to a median
score of 1.5 (range 0.5 to 3) (P <0.05; Figure 2A,B,C) and
RANK with a significant decrease from a median level of
3 (range 1.5 to 3) to a median score of 1 (range 0.5 toFigure 2 Methotrexate decreases expression of RANKL and RANK in t
Brown immunohistochemistry (diaminobenzidine) staining of cell surface m
receptor activator of the NF-κB ligand (RANKL) expression in early, untreate
trexate (MTX) treatment (B), as evaluated by semi-quantitative double-blind
expression in early, untreated RA synovium (D) decreased significantly follo
double-blind microscopic analysis (F). Synovial osteoprotegerin (OPG) expr
of MTX treatment, as evaluated by semi-quantitative double-blind microsco2.5) (P <0.05; Figure 2D,E,F). No changes were observed
in the expression of OPG (median score of 2 (range 1 to 3)
before the treatment, and a median score of 2 (range
1 to 2.5) following treatment) (Figure 2G,H,I). These
changes resulted in a significant decrease of the synovial
RANKL/OPG ratio from a median of 1.25 (range 0.75
to 2) to a median of 0.75 (range 0.25 to 1.7) (P <0.05;
Figure 3). Similar results were observed when the synovial
RANKL/OPG ratio was analyzed by computer-assisted
image analysis, showing a significant (P <0.05) decrease
from a median of 2.6 (range 1.3 to 7.3) to a median of 1.8
(range 0.2 to 5.1). The synovial RANKL/OPG ratio at
baseline was significantly higher (P <0.05) in patients with
erosion progression at 1-year follow-up (median of 1.5,
range 1 to 2) as compared with those with no progression
(median 1.1, range 0.75 to 1.3). No correlation washe rheumatoid synovium of early-untreated rheumatoid arthritis.
arkers in synovial biopsies of early rheumatoid arthritis (RA). Synovial
d RA synovium (A) decreased significantly following 8 weeks of metho-
microscopic analysis (C). Synovial receptor activator of NF-κB (RANK)
wing 8 weeks of MTX treatment (E), as evaluated by semi-quantitative
ession in early, untreated RA (G) is not changed following 8 weeks (H)
pic analysis (I). *p<0.05.
Figure 3 Methotrexate decreases the synovial RANKL/OPG ratio
in early-untreated rheumatoid arthritis. Synovial receptor activator of
the NF-κB ligand (RANKL)/osteoprotegerin (OPG) ratio as evaluated by
semi-quantitative double-blind microscopic analysis. *P <0.05.
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and CD marker expression.
Methotrexate reduces RANKL expression in vitro in
synovial-derived fibroblast cells and in osteoblast-like
cells
MTX reduced in vitro expression of mRNA RANKL ex-
pression in RA synovial-derived fibroblasts to 0.5 ± 0.08-
fold of the control (P <0.05; Figure 4A), with no change
in OPG mRNA expression (Figure 4B). A similar change
was observed when cellular protein levels were analyzed
by western blot (Figure 4C), with a decrease in RANKL
expression up to 0.5 ± 0.1-fold of the control (P <0.05;
Figure 4D) and no change in OPG expression (Figure 4E).
Analysis of soluble proteins expression in the cell culture
supernatants revealed a significant decrease of the RANKL
levels to a maximum of 0.7 ± 0.03-fold of the control
(P <0.05; Figure 4F), with no changes in the levels of sol-
uble OPG (Figure 4G). Similar results were obtained in
cultures of osteoblast-like tumoral cells, as shown in detail
in Additional file 3. The MTX effect on RANKL expres-
sion was not mediated through cell death induction be-
cause incubation of either fibroblast-like or osteoblast-like
cells with MTX failed to induce either necrosis or apop-
tosis (Additional file 4).
Methotrexate decreases osteoclasts formation and bone
resorption
Conditioned medium from osteoblast-like tumoral cells
exposed to MTX reduced pre-osteoclast formation
from CD14+ precursors in the presence of M-CSF alone
(Figure 5A,B,C). Direct exposure of osteoclast precursors
to MTX in presence of RANKL and M-CSF resulted in a
significant decrease in the number of both pre-osteoclastsand mature osteoclasts to a maximum of 0.4 ± 0.1 of the
control for pre-osteoclasts and 0.8 ± 0.03 for osteoclasts
(Figure 5D,E,F). The decrease in osteoclast formation was
paralleled by a significant reduction of synthetic bone re-
sorption area from a mean ± standard error of the mean
of 60% ± 4.7 in the controls to 32.4% ± 2.7 when MTX was
added to the culture (Figure 5G,H,I,J,K). This effect was
not mediated through cell death induction because incu-
bation of osteoclasts precursors with MTX failed to in-
duce either necrosis or apoptosis, as shown in Additional
file 4.
Discussion
MTX is the most common anti-rheumatic drug with a
bone-sparing effect in some RA patients. We demon-
strate here that MTX treatment modulates the RANKL/
RANK/OPG pathway and inhibits osteoclasts matur-
ation, two potential molecular mechanisms behind this
clinical observed effect.
Our immunohistochemistry study is the first to inves-
tigate expression and modulation of the RANKL/RANK/
OPG pathway in very early RA in disease-modifying anti-
rheumatic drug-naïve patients. One earlier study in a
heterogeneous RA population with median disease
duration of 4 years and a large array of different anti-
rheumatic treatments (including six patients only treated
with MTX) suggested that successful disease-modifying
anti-rheumatic drug treatment results in a significant de-
crease in the synovial RANKL/OPG ratio probably related
to the decrease in inflammation. Our results, however,
show that synovial RANKL and RANK expression are not
completely dependent on local inflammation as demon-
strated by the lack of association between these markers
and synovial inflammation (evaluated by immunohisto-
chemistry for CD3 and CD68). We have previously shown
that intra-articular glucocorticoids decrease synovial ex-
pression of RANKL in the injected joint [8]. Intra-
articular glucocorticoids in other joints than those that
were subjected to arthroscopies were allowed in the
current study according to clinical indication. Distant ef-
fects on the joint subjected to arthroscopy cannot be
excluded, but even if present they should be minimal.
The baseline synovial RANKL/OPG ratio was higher
in patients showing radiographic progression during the
first year of disease. This finding is in line with a previous
study showing that the serum RANKL/OPG ratio is the
best predictive marker for annual progression of radio-
logical damage [14] independent of therapy. However, the
small number of patients included in the current study
precludes a definite conclusion and needs confirmation in
a larger number of patients.
We further examined the effects of MTX in vitro in pri-
mary synovial-derived fibroblast and tumoral osteoblast-
like cells. Long and repeated exposure in vivo, with local
Figure 4 Methotrexate decreases mRNA and protein expression of RANKL and RANK in rheumatoid arthritis synovial-derived fibroblasts.
A significant decrease in the receptor activator of the NF-κB ligand (RANKL) mRNA levels (A) with no changes in osteoprotegerin (OPG) mRNA
levels (B) in the presence of methotrexate (MTX). Representative blots and graphs showing decrease of cellular RANKL protein expression
(C and D) with no changes in the cellular OPG expression (C and E) in the presence of MTX. Decrease of soluble RANKL protein expression (F) with
no changes in the soluble OPG expression (G) in the presence of MTX, where results are quantified by enzyme-linked immunosorbent assay. *p<0.05.
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olites with vastly extended tissue half-lives [16], is challen-
ging to reproduce in vitro. After extensive titration work,
we chose to use doses that are higher than previous re-
ported serum concentrations in RA patients [17,18] but
are in the range of doses previously shown to be anti-
inflammatory in vitro [19]. MTX decreases mRNA and
protein RANKL expression without influencing OPG ex-
pression, in both synovial-derived fibroblasts and cultured
osteoblast-like cells. We have previously demonstrated
that TNF antagonists (such as etanercept and infliximab)
are able to decrease the RANKL/OPG ratio through upreg-
ulation of synovial OPG expression [7]. We demonstrate
here that MTX, similar to intra-articular corticosteroids
but in contrast to TNF antagonists, modulates the syn-
ovial RANKL/OPG system through downregulation of
RANKL. Taken together, our findings offer a rationale
for the better effect observed following combinationtherapy with TNF antagonists and MTX than each
treatment alone, with a potential dual-positive modu-
lation of the RANKL/OPG system, resulting in better
bone protection.
Previous reports demonstrated that MTX prevents os-
teoclastogenesis through decrease of RANKL expression
[9,10]. We further demonstrate an additional direct ef-
fect of MTX on osteoclast precursor cells despite the
presence of excess exogenous RANKL. Interestingly this
effect is not modulated through cellular cytotoxicity as
demonstrated by a lack of cell death induction in cells
exposed to MTX. Previously, MTX was reported to sup-
press activation of the NF-κB signaling pathway [20],
and NF-κB was reported essential for RANK-expressing
osteoclast precursors to differentiate in TRAP-positive
osteoclasts in response to RANKL and other osteoclas-
togenetic cytokines [21]. Further studies are needed to
investigate whether MTX-induced suppression of the
Figure 5 Methotrexate suppresses osteoclastogenesis. Tartrate-resistant acid phosphatase (TRAP) staining showing reduction in the number
of TRAP-positive cells when CD14+ osteoclast precursors were incubated with supernatants from methotrexate (MTX)-treated osteoblast-like cells
(A) as compared with supernatants from nontreated osteoblast-like cells (B); arrow indicates a TRAP-positive pre-osteoclast. The fold decrease in
the number of TRAP-positive pre-osteoclasts in MTX-treated osteoblast-like cells as compared with supernatants from nontreated osteoblast-like
cells (C). TRAP staining showed a reduction in the number of TRAP-positive cells when CD14+ osteoclast precursors were incubated with MTX
(D) as compared with control (E) in the presence of exogenous macrophage colony-stimulating factor M-CSF and RANKL; arrow indicates a
TRAP-positive multinucleated osteoclast. The fold decrease in the number of TRAP-positive pre-osteoclasts and TRAP-positive multinucleated
(more than two nuclei) osteoclasts in MTX-treated cultures as compared with control cultures (F). Von Kossa brown stained osteologic discs
(G) showing large clear resorption areas (arrow) that are reduced following MTX exposure (H). Inverted images with the black surface representing
the bone resorption areas in the controls (I) and MTX-exposed cultures (J), allowing quantification of data as seen in the adjacent graph (K). *p<0.05.
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cursors resistant to osteoclastogenesis.
In conclusion, we have demonstrated that untreated,
early RA is characterized by an imbalanced synovial ex-
pression of RANKL, RANK and OPG independent of
local inflammation. This could be reverted by MTX
treatment in some but not all patients. MTX prevents
osteoclastogenesis by a dual mechanism involving bothreduction of RANKL expression and direct effects on
osteoclast precursors independent of RANKL.
Conclusions
Synovial membrane of early-untreated RA is character-
ized by a high RANKL/OPG ratio. Treatment with MTX
directly affects the RANKL/RANK/OPG system and in-
hibits osteoclastogenesis in early, untreated RA.
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Additional file 1: Is a table listing detailed demographic
information of the RA patients included in the study. NSAID,
nonsteroidal anti-inflammatory drugs; DAS, disease activity score; SEM,
standard error of the mean; ACPA, anti-citrullinated protein antibodies;
RF, rheumatoid factor.
Additional file 2: Presents supplementary methodological
information. Description of the RANKL and OPG primer sequences.
Additional file 3: Shows that MTX decreases mRNA and protein
expression of RANKL and RANK in osteoblast-like tumoral cells.
Graph showing a significant decrease in the RANKL mRNA levels with no
changes in OPG mRNA levels in the presence of MTX (A). Representative
blot and graphs showing decrease of cellular RANKL protein expression
with no changes in the cellular OPG expression in the presence of MTX
(B). Graphs showing decrease of soluble RANKL protein expression with
no changes in the soluble OPG expression in the presence of MTX (C),
where results are quantified by enzyme-linked immunosobent assay
(ELISA). rtPCR, reverse transcriptase polymerase chain reaction.
Additional file 4: Shows the lack of apoptosis induction by MTX.
Representative cytometry plots showing that MTX does not induce
apoptosis and graphs representing quantification of Annexin-V-positive
cells following MTX exposure in synovial fluid mononuclear cells (SFMC),
PBMC, Saos-2 (osteoblast-like tumoral cells) and synovial fibroblasts.
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